Finding the path of least antimicrobial resistance in pyelonephritis

Clinical Infectious Diseases

Volumn 47, Issue 9, 2008, Pages 1159-1161

  Lautenbach, Ebbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; COST OF ILLNESS; CYSTITIS; DRUG EXPOSURE; EMERGENCY WARD; ENTEROBACTER INFECTION; MORTALITY; NOTE; PREVALENCE; PRIORITY JOURNAL; PYELONEPHRITIS; RISK ASSESSMENT; RISK FACTOR; URINALYSIS; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI;

ADULT; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; PYELONEPHRITIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 53349128063     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592251     Document Type: Note

References (17)

1. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population-based epidemiologic analysis of acute pyelonephritis. Clin Infect Dis 2007; 45:273-80.
2. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol 2003; 13:144-50.
3. Brown P, Ki M, Foxman B. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 2005; 23:1123-42.
4. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29:745-58.
5. Talan DA, Krishnadasan A, Abrahamian FM, Stamm WE, Moran GJ; EMERGEncy ID NET Study Group. Prevalence and risk factor analysis of trimethoprim- sulfamethoxazole- and fluoroquinolone-resistant Escherichia coli infection among emergency department patients with pyelonephritis. Clin Infect Dis 2008; 47:1150-8 (in this issue).
6. Lautenbach E, Strom BL, Nachamkin I, et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, (1989-2000): Differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38:655-62.
7. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 162:2469-77.
8. Metlay JP, Strom BL, Asch DA. Patterns of antimicrobial drug exposure and subsequent risk of drug resistant urinary tract infections. J Antimicrob Chemother 2003; 51:963-70.
9. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis 2002; 34:1061-6.
10. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med 1999; 14:606-9.
11. Smith SP, Manges AR, Riley LW. Temporal changes in the prevalence of community-acquired antimicrobial-resistant urinary tract infection affected by Escherichia coli clonal group composition. Clin Infect Dis 2008; 46:689-95.
12. Colgan R, Johnson JR, Kuskowski M, Gupta K. Risk factors for trimethoprim-sulfamethoxazole resistance in patients with acute uncomplicated cystitis. Antimicrob Agents Chemother 2008; 52:846-51.
13. Metlay JP, Hardy C, Strom BL. Agreement between patient self-report and a Veterans Affairs national pharmacy database for identifying recent exposures to antibiotics. Pharmacoepidemiol Drug Saf 2003; 12:9-15.
14. Hooton TM, Besser R, Foxman B, Fritsche TR, Nicolle LE. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. Clin Infect Dis 2004; 39:75-80.
15. Norris DL, Young JD. Urinary tract infections: diagnosis and management in the emergency department. Emerg Med Clin North Am 2008; 26:413-30.
16. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA 2000; 283:1583-90.
17. McGregor JC, Harris AD, Furuno JP, Bradham DD, Perencevich EN. Relative influence of antibiotic therapy attributes on physician choice in treating acute uncomplicated pyelonephritis. Med Decis Making 2007; 27:387-94.